FY2024 · ended Dec 31, 2024 · Revenue $7.14M, -66.0% YoY · Filed Mar 31, 2026
Tvardi Therapeutics, Inc. (TVRD) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $25.8 million in cash and investments and $145,000 in total debt.
Revenue (TTM)
$7.57M
-55.3% vs year-ago TTM
Net income (TTM)
$-34.77M
+63.8% vs year-ago TTM
Operating cash flow (TTM)
$-25.03M
+0.1% vs year-ago TTM
Free cash flow
$-19.35M
+79.5% vs prior year
EPS (TTM)
$-12.26
-205.5% vs year-ago TTM
Dividend per share (TTM)
$0.00
Shares outstanding
9.38M
+105.1% vs prior year
Net cash
$25.70M
as of Jun 30, 2026
Operating margin
-36.9%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TVRD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Sugar Land, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1346830
- Former names
- Cara Therapeutics, Inc. (until Apr 11, 2025); Cara Therapeutics Inc (until Jul 21, 2010)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $7.1M | $21.0M | $41.9M | $23.0M |
| Operating income | -$26.7M | -$28.1M | -$121.5M | -$87.5M | -$89.1M |
| Net income | -$18.2M | -$29.4M | -$118.5M | -$85.5M | -$88.4M |
| Diluted EPS | -$3.26 | -$11.42 | -$26.26 | -$19.12 | -$1.74 |
| Operating cash flow | -$23.5M | -$18.3M | -$92.1M | -$78.7M | -$60.1M |
| Free cash flow | — | -$19.4M | -$94.5M | -$78.8M | -$60.1M |
| Total assets | $32.1M | $35.2M | $125.8M | $182.2M | $247.1M |
| Total liabilities | $11.1M | $40.8M | $68.8M | — | — |
| Stockholders' equity | $20.9M | -$91.1M | -$62.1M | $158.8M | $227.5M |
| Cash and investments | $30.8M | $31.6M | $51.8M | $63.7M | $236.8M |
| Total debt | $201,000 | — | $6.1M | $1.9M | $3.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Other events
|
Jul 17, 2026 | Jul 17, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 7, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 9, 2026 |
All 809 Tvardi Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.